Enabling Reliable Heparin Sodium Nucleotidic Impurity Analysis with the Alliance™ iS Bio HPLC System with PDA Detector

Significance of the topic

Heparin sodium is a critical anticoagulant derived from animal tissue and therefore inherently susceptible to low‑level nucleotidic impurities that can affect drug safety and efficacy. Regulatory monographs (USP) require targeted testing for these impurities, including an on‑autosampler enzymatic digestion step at controlled temperature. Reliable implementation of this USP method places specific demands on HPLC hardware and consumables: tight sample temperature control during digestion, minimized non‑specific adsorption (NSA) for metal‑sensitive nucleosides, and sensitive UV/PDA detection to quantify trace components.

Study objectives and overview

This application study evaluated the suitability of the Alliance iS Bio HPLC System with PDA Detector for carrying out the USP monograph procedure for heparin nucleotidic impurity analysis. Key goals were to confirm that the system can: meet USP system suitability criteria (precision, resolution, signal‑to‑noise), provide reproducible enzymatic digestion in the autosampler at 37 °C ±1 °C, and minimize NSA for reliable quantitation of low‑level nucleoside impurities.

Methodology

The workflow adhered to the USP monograph for nucleotidic impurities with the following practical adaptations and controls:

• Sample and standards: Adenosine stock and diluted standards prepared per USP; an eight‑nucleoside identification mix (uridine, guanosine, cytidine, thymidine, 2′‑deoxyadenosine, 2′‑deoxyguanosine, 2′‑deoxycytidine, 5‑methyl‑2′‑deoxycytidine) used for peak ID and resolution checks.
• Enzymatic digestion: Heparin samples mixed with enzyme digest solution in total‑recovery autosampler vials and incubated in the autosampler at 37 °C for at least 1 hour, with temperature tolerance ±1 °C as required by the USP method.
• Chromatography: An adjusted gradient compatible with modern column chemistries was used; method parameters (flow rate and injection volume) were adapted from USP guidance to suit the selected column packing.
• Data handling: Empower CDS was used for acquisition and processing; S/N and area‑based impurity calculations were performed per USP, including determination of the area reject value Q.

Used instrumentation

Instrument and key consumable details reported in the study:

• LC system: Alliance iS Bio HPLC System configured with MaxPeak High Performance Surfaces (HPS) Technology to reduce NSA.
• Detector: PDA Detector; primary 2D channel at 260 nm (4 nm resolution), 3D acquisition across 200–400 nm (1 nm resolution), data rate 5 Hz.
• Column: XSelect Premier CSH C18, 3.5 µm, 4.6 × 150 mm (selected to improve peak shape versus legacy 4 µm L1 packing).
• Temperatures: Column 20 °C ±3 °C; sample compartment maintained at 37 °C ±1 °C (measured stability ~37.085–37.120 °C during digestions).
• Injection: 10 µL; flow rate ~1.143 mL/min (adjusted for chosen column).
• Mobile phases: A = 0.02 M ammonium acetate in water; B = acetonitrile; additional wash/purge solvents per USP adjustments.
• Vials: Total‑recovery 12 × 32 mm clear glass with PTFE/silicone septa.

Main results and discussion

System suitability and analytical performance:

• Column choice and method adjustments: The USP‑specified 4 µm L1 column produced undesirable tailing and failed resolution objectives in initial testing. Switching to a modern CSH C18 packing (3.5 µm) with minor flow and injection adjustments restored acceptable peak shape and USP resolution criteria.
• System suitability metrics: Area precision, retention precision, resolution, and sensitivity met USP acceptance criteria. PDA detector provided robust sensitivity with measured S/N ≈ 47 for the adenosine standard (USP requires NLT 10).
• Enzymatic digestion reproducibility: Three independently prepared digests incubated concurrently in the autosampler produced highly consistent impurity profiles. Individual impurity contents varied by no more than 0.008% between digests and total nucleotidic impurity values were consistent within 0.010%.
• Thermal control: Sample compartment temperature traces showed excellent stability within the ±1 °C requirement, supporting reproducible enzymatic activity and digestion efficiency.
• Chromatography quality: Overlaid chromatograms of system suitability, standards, and sample exhibited repeatable retention and baseline stability with no significant co‑elution or interfering peaks identified for the monitored nucleosides.

Benefits and practical applications

The evaluated hardware and method adaptations provide practical advantages for regulated heparin testing workflows:

• Regulatory compliance: System performance meets USP monograph criteria for nucleotidic impurity analysis, enabling use in QC release and stability testing.
• Reproducible enzymatic digestion: Accurate autosampler temperature control enables on‑instrument digestion without separate incubators, simplifying sample handling and reducing hands‑on time.
• Reduced NSA: MaxPeak HPS surfaces minimize losses of metal‑sensitive nucleosides, improving accuracy at trace levels.
• Operational robustness: Modern column chemistries combined with adjusted flow/injection parameters yield better peak shape and easier integration than legacy packings.

Future trends and potential applications

Opportunities to further enhance nucleotidic impurity testing and broader biopharmaceutical impurity workflows include:

• MS integration: Coupling LC to mass spectrometry would enable orthogonal confirmation of nucleoside identity and improved sensitivity for trace-level characterization.
• Advanced surface chemistries: Continued development of low‑adsorption flow paths and novel stationary phases will reduce method transfer issues and improve robustness for challenging analytes.
• Automation and sample prep: Automated reagent addition, digestion mixing, and vouchered autosampler workflows can increase throughput and reduce operator variability.
• Real‑time process monitoring: Adapting similar analytical concepts for PAT (process analytical technology) could support in‑process control of biologically derived raw materials.
• Regulatory harmonization: Standardized approaches across pharmacopeias and adoption of ruggedized, validated LC configurations will simplify cross‑laboratory method implementation.

Conclusion

This application demonstrates that the Alliance iS Bio HPLC System with PDA Detector, equipped with MaxPeak HPS surfaces and paired with a modern CSH C18 column and adjusted method parameters, reliably implements the USP nucleotidic impurity procedure for heparin sodium. The system satisfied USP system suitability requirements, achieved high PDA sensitivity, and delivered reproducible on‑autosampler enzymatic digestions with tight temperature control. Reported impurity quantitation was consistent across independent digests, indicating the platform is suitable for regulated QC laboratories performing heparin impurity testing.

References

1. The United States Pharmacopeia, USP‑NF <621> Chromatography.
2. The United States Pharmacopeia, Heparin Sodium – Nucleotidic Impurities.